R egenerative stem cell therapy to promote cardiac repair has been a target of interest in the past 10 years to prevent heart failure after an acute myocardial infarction (AMI). 1, 2 Various different stem cells have been investigated for their ability to repair the heart. 3 Mesenchymal stem cells (MSCs) seem to be a potent candidate to date. The mechanism of action of MSC is primarily based on the release of paracrine factors to the myocardium. 4 However, retention and survival of stem cells in the myocardium after intracoronary infusion remains an issue in cell-based therapy, because only a limited number of surviving stem cells remain in the myocardium, thereby limiting the potential benefit of the therapy. [5] [6] [7] CellBeads, which consist of alginate-encapsulated MSCs (eMSCs; BTG International Germany GmbH, Alzenau, Germany), were developed to improve survival of cells in the myocardium, thereby elongating the release of cardioprotective proteins into the infarcted myocardium. These eMSCs secrete endogenous paracrine factors that include vascular endothelial growth factor, monocyte chemotactic protein-1, interleukin (IL)-6, IL-8, glial-derived neurotrophic factor, and neurotrophin-3 and are genetically modified to produce glucagon-like peptide-1 (GLP-1) fusion protein, which comprises 2 GLP-1 molecules bound by an intervening peptide, extending its half-life in vivo. [8] [9] [10] [11] [12] Among its beneficial effects Background-Engraftment and survival of stem cells in the infarcted myocardium remain problematic in cell-based therapy for cardiovascular disease. To overcome these issues, encapsulated mesenchymal stem cells (eMSCs) were developed that were transfected to produce glucagon-like peptide-1, an incretin hormone with known cardioprotective effects, alongside MSC endogenous paracrine factors. This study was designed to investigate the efficacy of different doses of intracoronary infusion of eMSC in a porcine model of acute myocardial infarction (AMI). Methods and Results-One hundred pigs were subjected to a moderate AMI (posterolateral AMI; n=50) or a severe AMI (anterior AMI; n=50), whereupon surviving animals (n=36 moderate, n=33 severe) were randomized to receive either intracoronary infusion of 3 incremental doses of eMSC or Ringers' lactate control. Cardiac function was assessed using invasive hemodynamics, echocardiography, and histological analysis. A trend was observed in the moderate AMI model, whereas in the severe AMI model, left ventricular ejection fraction improved by +9.3% (P=0.004) in the best responding eMSC group, because of a preservation of left ventricular end-systolic volume. Arteriolar density increased 3-fold in the infarct area (8.4±0.9/mm 2 in controls versus 22.2±2.6/mm 2 in eMSC group; P<0.001). Although not statistically significant, capillary density was 30% higher in the border zone (908.1±99.7/mm 2 in control versus 1209.0±64.6/mm 2 in eMSC group; P=ns).
in type 2 diabetes mellitus, GLP-1 has antiapoptotic and cardioprotective properties. [13] [14] [15] [16] Infusion of a GLP-1 analogue, exenatide, after AMI resulted in a reduction of infarct size, thereby improving cardiac function in a preclinical and clinical setting. [14] [15] [16] [17] [18] [19] [20] However, GLP-1 has a short half-life in vivo. Therefore, infusion directly at target site or, in case of the GLP-1-eluting eMSC, production directly on-site could render a long-term release of GLP-1 especially because of the prolonged half-life of the GLP-1 fusion protein. eMSCs have a diameter of 170 μm resulting in entrapment in the coronary system after intracoronary infusion. 10, 21 The alginate shell surrounding the cells allows diffusion of oxygen and nutrients through the pores of the alginate shell into the MSC as well as diffusion of paracrine factors out of the bead. Moreover, the alginate shell protects the MSC against a host immune response. 21 Previously, intracoronary infusion of >60 000 eMSC in naïve and infarcted porcine myocardium was well tolerated without any sign of microvascular obstruction (MVO). 10 The alginate-eMSCs remain viable for ≥7 days, still secreting the recombinant GLP-1 and MSC paracrine factors. 10 In this study, we aimed to explore the long-term safety, feasibility, and efficacy of incremental doses of intracoronary delivered eMSC in a moderate and severe porcine AMI model. The primary end point in this study was cardiac function as assessed by echocardiography. The secondary end points were cardiac contractile function as measured by pressure-volume loop analysis, infarct size, collagen density, capillary density, arteriole density, apoptosis, and cardiomyocyte size.
Methods
A total of 100 female Landrace pigs (Van Beek, Lelystad, The Netherlands; 70±5 kg) were randomized in this study. All animal experiments were performed according to the Guide for care and the use of laboratory animals and all experiments were previously approved by the institutional animal welfare committee of the University of Utrecht, Utrecht, The Netherlands. The efficacy of intracoronaryadministered eMSC was investigated in a moderate size infarct (posterolateral AMI [left circumflex artery model; study 1]) and in the second phase in a severe anterior AMI model (left anterior descending artery model; study 2).
Experimental Design
The design of this study is summarized in Figure 1 . Briefly, 100 female pigs underwent an AMI (50 in each group). Pigs that survived infarct induction (n=73; n=36 in the moderate infarct study and n=37 in the severe AMI study) were divided into 4 groups in each study to receive either intracoronary infusion of eMSC or Ringers' lactate (RL) control solution. The safety ≤1 week after intracoronary infusion of GLP-1 eMSC was previously described. 10 The safety ≤8 weeks was investigated in this study and was defined as mortality, occurrence of ventricular arrhythmias, and the occurrence of heart failure (fluid retention, need for treatment with heart failure medication). Cardiac function was assessed by echocardiography and pressurevolume loop analysis (in the severe anterior model only). Eight weeks after infarct induction animals were terminated and the hearts were excised for infarct size calculations and histological analysis.
Encapsulated MSCs
The eMSC used in this study had an outer diameter of 170 μm and contained 75 human MSC stably lentivirally transfected to release a GLP-1 fusion protein, which comprises 2 GLP-1 molecules bound by an intervening peptide, giving it an extended half-life in vivo (CellBeads, BTG Germany, Alzenau, Germany). 8, 10, 12 Animals were randomized to a treatment group 60 minutes after the onset of ischemia. eMSCs were then thawed and dissolved in 100 mL RL. A final concentration of 200 to 600 eMSC/mL, depending on the dose, or 100 mL of RL was intracoronary infused in 50 minutes at an infusion rate of 2 mL/min via a microcatheter (Twin Pass catheter; Vascular Solutions, Minneapolis) that was inserted through an 8F JL4 guiding catheter through a cannulated carotid artery. The eMSCs were infused at the exact site of the previous occlusion 30 minutes after inducing reperfusion in both MI models. All solutions were color coded and administered in a blinded fashion.
Study 1: A Moderate Posterolateral Infarct
All pigs were prepared, anesthetized, intubated, and ventilated according to a standardized protocol described in the Data Supplement. An 8F sheath (Cordis, Miami) was introduced into the carotid artery and an angiogram of the left coronary tree was acquired using an 8F JL4 guiding catheter (Boston Scientific, Natick). A posterolateral myocardial infarction was induced by inflation of an angioplasty balloon in the proximal left circumflex artery for 90 minutes (Trek, 3.5-4.0×12; Abbott, IL). Animals were randomized into 4 groups: 20 000 eMSC (n=8), 40 000 eMSC (n=9), 60 000 eMSC (n=10), or RL control solution (n=9) after 60 minutes of ischemia. The thrombolysis in myocardial infarction (TIMI) flow in epicardial coronary arteries was registered before, during, and after infusion of eMSC to rule out potential MVO. Both antegrade flow of contrast and outwash of contrast were observed. To further quantify MVO, coronary flow reserve (CFR) was measured before and after eMSC infusion and at 8-week follow-up (ComboWire; Volcano, Zaventem, Belgium; see Data Supplement). All animals received a Reveal event recorder for the detection of arrhythmic events (Medtronic, Tilburg, The Netherlands). Cardiac function was assessed using 2-dimensional (2D) echocardiography at baseline, after infarct induction, and at 8-week follow-up. Left ventricular ejection fraction (LVEF) and LV volumes derived from 2D echocardiography were calculated by the modified Simpson rule (see Data Supplement). 22 All analyses were performed by an investigator blinded for the therapy allocation. At 8 weeks (±3 days) after MI, animals were anesthetized, intubated, and ventilated according to the institutional protocol (see Data Supplement). The Reveal event recorder was interrogated. After assessment of cardiac
WHAT IS KNOWN
• Myocardial infarction is hallmarked by a loss of cardiomyocytes decreasing the contractile function of the heart and may lead to heart failure.
• The beneficial effect of mesenchymal stem cell therapy after myocardial infarction is predominantly related to paracrine factors secreted by this cell type.
• Glucagon-like peptide-1 analogues reduce infarct size after myocardial infarction in experimental studies and clinical trials.
WHAT THE STUDY ADDS
• The 170-μm alginate-encapsulated glucagon-like peptide-1-eluting mesenchymal stem cells (encapsulated mesenchymal stem cells) are efficacious in a porcine model of myocardial infarction.
• Encapsulated mesenchymal stem cell infusion is safe without serious adverse effects and treatment with 20 000 encapsulated mesenchymal stem cell improved cardiac function 8 weeks after myocardial infarction. function as described above, animals were terminated and the heart was excised.
Study 2: Severe Anterior AMI Model
A severe anterior AMI was induced by a sternotomy and ligation of the mid-left anterior descending artery distal to the first diagonal for 90 minutes using a prolene ligature. An open chest procedure was applied in this phase of the study to reduce perioperative mortality. Previous studies that applied a closed chest left anterior descending artery occlusion experienced a mortality rate of 40% because of ventricular fibrillation during infarct induction, the animal welfare committee did therefore not allow a closed chest procedure and we had to change the protocol to an open chest procedure in which defibrillation directly on the heart was possible, thereby enhancing periprocedural survival. Because of the open chest procedure, epicardial 3D echocardiography was performed after reperfusion and animals with an LVEF >45% were excluded from the study (n=4). The remaining animals were randomized into 4 groups: 10 000 eMSC (n=6), 20 000 eMSC (n=9), 40 000 eMSC (n=8), or RL buffer as control solution (n=10). Based on the results of study 1, we decided to infuse lower doses of eMSC in this study. A Twin Pass catheter was then positioned in the target vessel and placebo or cell solutions were administered at a fixed infusion rate of 2 mL/min. TIMI flow was assessed before, during, and after infusion of eMSC or placebo solution. Three-dimensional echocardiography was performed in this study at baseline, after infarct induction, and at 8-week follow-up. Because of the anatomic position of the porcine ribs, it is not possible to obtain clear 3D echocardiography images in a close chest model nor is it possible to obtain 2D-echocardiographic images directly after open chest surgery. We therefore decided to perform 3D echocardiography in this study at baseline, after AMI, and at 8-week follow-up, alongside 2D echocardiography at baseline and at 8-week follow-up (see Data Supplement). A Reveal recorder was implanted for the detection of arrhythmic events. At 8-week follow-up, functional measurements were performed, whereupon the heart was excised and processed as described above. Adding to the 2D and 3D echocardigraphy data, pressure-volume loop analysis was performed to obtain data on cardiac contractility at week followup in this study. The exact protocol has been described elsewhere (Methods in the Data Supplement). 23
Tissue Collection and Infarct Size Analysis
At 8-week follow-up, the hearts were excised and processed for determination of infarct size and (see Data Supplement), as previously described. 14, 24 
Assessment of Vascular Density, Collagen Density, and Cardiomyocyte Apoptosis
Paraffin-embedded biopsies were sectioned into 5-μm slices (see Data Supplement). Subsequently, the slides were stained for determination of vascular density, collagen density, and cardiomyocyte apoptosis using appropriate antibodies (see Data Supplement). Arterioles and capillaries were expressed as number per millimeter squared. Cardiomyocyte apoptosis was expressed as percentage apoptotic cardiomyocytes per view.
Quantitative Polymerase Chain Reaction Analysis of GLP-1 and Human Housekeeping Genes
Quantitative polymerase chain reaction analysis was performed to quantify expression of human GLP-1 and BNP (see Data Supplement for detailed description).
Statistical Analysis
Continuous data are presented as mean± SEM. The Δ represents the difference between post-AMI and 8-week follow-up and was first calculated for each animal individually whereupon the average per group was calculated. Comparison of mean values between groups was performed using a 1-way ANOVA, followed by Dunnett test to detect differences between treatment groups and control. Changes over LVEF, left ventricular end-diastolic volume, left ventricular end-systolic volume, and CFR over time were assessed using a linear mixed effects repeated measures model. P values <0.05 were considered significant. All analyses were performed using IBM SPPS Statistics 20 (Chicago).
Results

Study 1: Moderate Posterolateral AMI Model
Mortality and Arrhythmias
One animal in the control group died of ventricular fibrillation 1 day after the infarct procedure. Two animals in the 60 000 group died of ventricular fibrillation, 1 and 5 days after the infarct procedures, respectively. None of the animals needed to be treated for heart failure during follow-up and ventricular arrhythmias were not detected by the Reveal event recorder during the 8-week follow-up period in both groups.
Coronary Flow
Infusion of the 170-μm eMSC did not visually impede antegrade coronary flow up to infusion of 60 000 eMSC because all animals exhibited TIMI 3 flow directly after infusion. Outwash of contrast was slower in 2 of 8 pigs in the 60 000 group and 1 of 9 animals in the 40 000 group but this was still within the definition of TIMI 3. 25 CFR did not change after eMSC infusion confirming that MVO did not occur to a significant level directly after infusion ( Figure 2 ). Based on these results, it was decided to omit CFR measurements in study 2. At 8-weeks follow-up flow remained within TIMI 3 range in all groups. CFR did not change significantly over time within the groups (Figure 2 ).
LVEF and Left Ventricular Volumes
After infarct induction, no differences were observed on LVEF between groups, indicating comparable infarct size. At 8-week follow-up, LVEF was a higher, EF was observed in the 20 000 eMSC group opposed to control although this did not reach statistical significance (+6%; P=NS; Figure 3 ; Table I in the Data Supplement).
Infarct Size
Infarct size was only 9.6±1.3% in the control group opposed to 7.6±1.2% in the 20 000 group (P=NS). The 40 000 and 60 000 groups, however, showed similar infarcts sizes as the ringer lactate control (9.1±1.2 and 9.3±1.8%, respectively; Figure 4A ).
Vascular Density, Collagen Density, and Cardiomyocyte Apoptosis
Capillary density in border and remote areas was not enhanced in all groups (Table II and Table II in the Data Supplement), whereas eMSC did not enhance arteriole formation in the border and remote segments. Moreover, collagen deposition and cardiomyocyte apoptosis were not affected ( Figure IE 
Study 2: Severe Anterior AMI Model
Mortality and Arrhythmias
One animal in the control group died of ventricular fibrillation 1 day after the infarct procedure. None of the animals needed to be treated for heart failure during follow-up and ventricular arrhythmias were not detected by the Reveal event recorder (Figure 1 ). Outwash of contrast was decreased (TIMI 2) in 43% of the animals in the 40 000 group and none of the animals in the other groups directly after infusion and at 8-week follow-up.
Improvement in LVEF
In this phase of the study, both 2D echocardiography and 3D echocardiography were applied. On 3D echocardiography, LVEF at baseline and after infarct induction was comparable between the groups (Table I in the Data Supplement; Figure 5 ). At 8-week follow-up, LVEF increased by +0.2±1.0% in the control group to 38.9±1.5%. A total of 20 000 eMSC improved LVEF by +9.3% to 44.7±1.2% (ANOVA: P=0.004; control versus 20 000, P=0.011; Table I in the Data Supplement). The increase in LVEF was mainly because of a preservation of left ventricular end-systolic volume, which decreased by −2.9±4.8 mL (20 000 eMSC) compared with an increase of +18.1±4.5 mL in control animals ( Figure 5 ). LVEF was comparable between 2D echocardiography and 3D echocardiography. LV volumes were 15 mL higher when measured by 2D echocardiography. The same significant effect in LVEF was seen on 2D echocardiography.
Cardiac Contractility
End-systolic pressure volume relationship, which reflects systolic contractile function, was dramatically increased by 230% in all treatment groups as opposed to control animals (6.5±1.3 mm Hg/mL in 20 000 eMSC group versus 1.9±0.5 mm Hg/mL in control; ANOVA: P=0.03, P=0.007 versus control). No differences were observed in other pressure-volume loop-derived parameters ( Figure 6 ; Table III in the Data Supplement).
Infarct Size
Although not significant, infarct size decreased by −20% in the 20 000 eMSC group ( Figure 4B ; Table III in the Data  Supplment) .
Vascular Density and Collagen Density
Capillary formation was not enhanced in border areas nor increased the capillary density in remote areas.
However, arteriolar density improved in the infarct area in all doses by +200% to 300% (22.2±2.6 versus 8.4±0.9/mm 2 ; ANOVA: P<0.001; Figure 7 ; Table II in the Data Supplement). Collagen density was not reduced in all dose groups.
Cardiomyocyte Apoptosis and Hypertrophy
Cardiomyocyte apoptosis was not influenced by eMSC treatment, which might be related to the late time point.
However, the surface area of the cardiomyocytes in the infarct-border zone of animals treated with 20 000 eMSC was ≈50% lower than in control and the other dose groups 
Discussion
In the current study, we investigated the efficacy and the optimal dose of encapsulated immune-protected MSC in a porcine model of AMI. This is the first time that the efficacy of microencapsulated MSC was investigated for the treatment of AMI. In the moderate infarct study, only a trend toward an improvement of cardiac function was observed. In the severe infarct study, LVEF was remarkably improved after eMSC infusion. Moreover, contractility was enhanced and neovascularization occurred.
Safety
In line with our previous results, eMSC infusion did not show side effects in a preclinical setting. 10 Previous studies suggested a reduction in TIMI flow and CFR after intracoronary of MSCs. 6, 26, 27 In this study, CFR did not significantly decrease directly either after infusion or at 8-week follow-up, indicating that MVO is not significant. Studies that report MVO after infusion of MSC, usually apply high doses, which could eventually result in obstruction. Several other preclinical and clinical studies have shown that under carefully controlled and monitored conditions, for example, slow infusion rate and low cell number, infusion of MSC or MSC-like stem cells or cardiospheres is well tolerated. 24, 28, 29 In the case of eMSC the same assumption could be made.
None of the animals developed heart failure during the follow-up period nor increased the incidence of arrhythmic events, indicating no side effects of eMSC therapy were observed during 8-week follow-up period.
Efficacy
When given intracoronary, 20 000 alginate eMSC significantly improve LVEF after a severe AMI. In the moderate infarction model we detected a trend, which was further explored in a more severe AMI model. As expected, the treatment effect turned out to be more pronounced in animals with more severe AMI, presumably because of a larger pharmacological window in the anterior model. This corresponds with a large meta-analysis by Jeevanantham et al 1 who concluded that patients with a LVEF <43% benefit more from cell-based cardiac repair. However, another meta-analysis failed to show a more prominent treatment effect of bone marrow mononuclear cells therapy in patients with lower LVEF. 3 If a treatment effect is already noticeable in a small infarct, the benefit will be expanded in a large infarct.
In absolute terms, intracoronary infusion of eMSC improved LVEF by +9.3% in severe anterior AMI model. The most effective dose in our study was 20 000 eMSC, which equals 1.6 million MSC, and is several orders of magnitude less than used in most preclinical trials using cultured MSC. However, eMSCs are better retained into the myocardium than unprotected stem cells culminating in prolonged protein release. This complicates direct comparison. Infusing <20 000 eMSC was not effective, suggesting that this dose is the lower limit. However, 40 000 eMSCs were not superior to lower doses, which does not necessarily preclude a dose-dependent effect but could also reflect unfavorable effects of incremental MVO undetectable by our CFR measurements or the adverse effects of a possible Pictures are taken at a ×10 magnification. Blue represents collagen, pink viable myocardium. Collagen deposition is more dense in the animals in the control group opposed to animals in the 20 000 eMSC group. C, Collagen density border area was not enhanced in treated animals. D, Example of trichrome stain in border area. E and F, Arterioles were stained by smooth muscle actin stain. E, In the infarct area, arteriole density was enhanced in treated animals (*P=0.04; +P=0.0001; =P=0.002 vs control). F, Representative images of smooth muscle actin stain in infarct area in a control animal and in a 20 000 eMSC animal at a ×10 magnification. G and H, Capillary density. G, A trend in a decreased capillary density was observed in 20 000 eMSC group. H, Representative images of isolectin stain in the border area of a control animal and a 20 000 eMSC animal, respectively, at a ×20 magnification.
xenogeneic immune response, which could be more severe in the high-dose group.
Clinical Applicability
Before possible translation of this product to a clinical treatment strategy, several issues should be addressed in future studies. First, lentiviral transduction for cell-based gene therapy remains subject to debate because insertional mutagenesis and thus tumorgenicity might be of increased risk. 30 This could influence the clinical applicability of the transduced eMSC. However, the MSCs are contained by the alginate and are unable to migrate to the host's tissue. Furthermore, the alginate exceeds the lifespan of the cells, with no exception observed in our study, making the risk for possible tumorgenicity rather low, in our opinion. Second, as described in previous studies, an increased inflammatory response around the eMSC has been detected in the present study, which can most likely be attributed to a xenogenic reaction. Future studies should determine whether this response is because of xenogenecity or a direct result of, for example, cell death inside the alginate microsphere. If the latter is the case then this would also influence the clinical applicability of this product because excessive inflammation is detrimental to infarct healing after MI. 31
Working Mechanism of Encapsulated GLP-1-Eluting MSC
Several preclinical studies showed that MSC therapy after AMI enhanced the formation of arterioles and capillaries by a release of paracrine factors. 24, 32 MSCs inside the alginate beads also have a proangiogenic effect. 33 Moreover, eMSC also improved angiogenesis in a hindlimb ischemia model and in porcine interposition grafts. 11, 33, 34 This proangiogenic effect might explain the observed preservation of cardiac function. 33, 34 Furthermore, the eMSC group shows a trend toward reduced fibrosis and improved myocardial viability in the infarct zone was observed, which could result in a reduction in total infarct size. 4, 24, 35 However, this effect was not statistically significant in our study, most likely based on limited numbers of animals. The trend toward less fibrosis could be explained by the secretion of immune-modulatory cytokines by MSC. IL-6 has been shown to increase the lifespan of neutrophils in the hostile post-AMI environment and improves healing of the infarct wound. 36 In addition, MSCs trigger the transition of classical M1 to anti-inflammatory M2 macrophages, thereby enhancing infarct healing via increased angiogenesis. 36 Alongside proangiogenic factors and immunomodulatory cytokines, MSCs secrete antiapoptotic factors that improve cell survival. 24, 35 In addition, eMSCs in this study were transfected to secrete recombinant GLP-1. Exenatide, a GLP-1 analogue, has shown to reduce infarct size and improve cardiac function in a pig AMI model. 14 Moreover, in 2 recent clinical trials in which exenatide was injected in patients with AMI (TIMI 0-1 flow) before PCI, infarct size was reduced by 50%, indicating that exenatide prevents reperfusion-mediated cell death. 15, 16 As eMSCs are infused within 30 minutes after reperfusion, the effect on infarct size could be related to limitation of reperfusion damage.
Next to its antiapoptotic effects, GLP-1 has been shown to directly improve cardiac contractility by increasing intracellular cyclic-AMP concentrations. 37 This latter effect could be responsible for the significant end-systolic pressure volume relationship improvement in all eMSC groups. The observed preservation in contractility could also be explained by strengthening of the heart's matrix by the infusion of alginate thereby preventing LV remodeling as previously was shown. 38, 39 However, in these studies, liquid alginate was used that diffuses through the vessel wall. 38 Although eMSC cannot leave the vessel lumen, they seem to provide structural support to the myocardium. The heart contains a population of resident cardiac stem cells. 40 It is hypothesized that MSC can activate these stem cells to stimulate infarct repair after an ischemic event. Suzuki et al 32 concluded from a porcine study, in which MSCs were intracoronary injected after AMI that MSCs stimulate endogenous cardiac stem cells to home to the site of injury and differentiate into cardiomyocytes. In addition to this, the MSC in their study differentiated into cardiac stem cells. Moreover, cardiomyocytes were stimulated to proliferate in animals that were treated with MSC. All these effects combined resulted in an increased cardiomyocyte nuclear density. In our study, cardiomyocyte nuclear density is increased in border and remote areas possibly suggesting that eMSCs stimulate myocardial salvage, which, in turn, results in a reduction of compensatory hypertrophy. Myocardial salvage in this study is based on a reduction of apoptosis by GLP-1 and most likely proliferation of adult cardiomyocytes. It was recently shown that IL-6 secreted by MSC-like stem cells stimulated cardiomyocyte proliferation. 41 As the eMSC produce IL-6, this would be the proposed working mechanism of cardiomyocyte proliferation in this study. Differentiation of MSC inside the beads could not have contributed to the increased number of cardiomyocytes because MSCs do not leave their shell. Activation of endogenous stem cells also remains a proposed mechanism of action. As was shown by Suzuki et al 32 and Houtgraaf et al 24 activation of resident cardiac stem cells is not detectable after 6 weeks after transplantation, the c-kit stain was omitted from current protocol. Moreover, cardiomyocyte proliferation could be not detected at 8-week follow-up in a previous study that used MSC. 24 Therefore, ki-67 stain was not executed.
Study Limitations
Despite our best efforts, this study has some limitations. First, cardiac function was not assessed by golden-standard cardiac MRI. However, echocardiographic measurements have shown excellent correlations with MRI. We are therefore confident that our findings would be corroborated by MRI. 42 In the 2 substudies we used slightly different protocols. In the more severe anterolateral model we used an open chest procedure to minimize high periprocedural mortality after mid-left anterior descending artery occlusion. The advantage of this open chest procedure enabled us to use epicardial 3D echocardiography alongside transthoracic 2D echocardiography in the anterior model. Although the 2 methods have shown to be in good concordance with one another, values should not be directly compared. Therefore, the 2 methods were both shown in the second phase. 43, 44 Second, in this study, we did not observe an increased MVO, as assessed by CFR, after eMSC infusion. However, variability in heart rate and arterial blood pressure might interfere with reliable CFR measurement. Because we did not do CFR measurements under atrial pacing, these parameters might have varied in the present study, thereby possibly influencing the sensitivity of the CFR measurements.
Third, we did not include all possible controls including eMSC not transduced to produce GLP-1, empty beads, or MSC only. This decision was based on our previous pilot data where we found beneficial effects on apoptosis and inflammatory response of eMSC opposed to empty alginate beads without MSC. Moreover, in a proof of concept study by Wright et al, 11 intracoronary infusion of macro-eMSC resulted in preserved LVEF and reduced infarct size when compared with empty alginate beads without cells and encapsulated human MSCs that were not transduced to express GLP-1. Because both the animal model and the eMSC preparation differed in this study, no firm conclusion can be drawn on the superiority of GLP-1-eluting eMSC used in the current study compared with nontransduced eMSC. Furthermore, a side-by-side comparison between eMSC and MSC would have been interesting. However, in this phase of the study, we decided that we first wanted to evaluate the efficacy of this new product before we performed a side-by-side comparison. Moreover, we did not know the optimal eMSC dose. If we would like to compare the efficacy of eMSC end MSC, the amount of MSC should be comparable between the groups. Here, the MSCs are derived from humans. This makes sense as we aimed to test the efficacy of the clinical product. Further research is needed to test whether allogeneic eMSCs are equal or even have a superior effect. As the GLP-1 analogue produced by the eMSC consists of a GLP-1 fusion protein with a short half-life, a direct comparison with native GLP-1 or GLP-1 analogues with prolonged half-life would be difficult to interpret.
There is no sign of degradation of the eMSC at 8-week follow-up. More research is needed to investigate how and when the eMSCs are degraded.
Conclusions
Intracoronary infusion of encapsulated GLP-1-eluting MSC resulted in a preserved LVEF in a porcine AMI model and is well tolerated ≤8-week follow-up. Infusion of eMSC improves cardiac function by preservation of end-systolic volume and cardiac contractility. eMSCs are able to prevent cardiomyocyte hypertrophy, enhance adaptive neovascularization, thereby limiting left ventricular remodeling. Importantly, eMSCs are an interesting platform that enables sustained paracrine delivery of MSC proteins and recombinant proteins to the damaged myocardium.
